Nordson narrows FY23 EPS view to $8.75 to $9.50 from $8.75-$10.10

As part of its Q1 earnings call yesterday, the company stated: "While the backlog remains robust at approximately $1 billion, the backlog is not consistent across the different businesses and is heavily weighted toward systems and medical interventional solutions. Order entry in recent weeks has decreased from the previous run rate and several customers have been pushing delivery dates out into the second half of fiscal 2023. Based on our current visibility, the company is updating its previously issued full-year revenue growth guidance to 0% to 3% over record fiscal 2022 and narrowing its adjusted earnings guidance to the range of $8.75 to $9.50." The company had previously guided FY23 revenue growth of 1%-7%.